JAK1 and congenital rubella syndrome: The selective JAK1 inhibitor itacitinib can reduce the release of cytokines associated with CRS in vitro and in vivo without impairing expansion and antitumor efficacy of anti-GD2, anti-EGFR, and anti-CD19 CAR T cells [106].